VEGF-B: a Survival, or an Angiogenic Factor?

Overview

Journal Cell Adh Migr

Specialty Cell Biology

Date 2009 Aug 18

PMID 19684473

Citations 44

Authors

Xuri Li

Chunsik Lee

Zhongshu Tang

Fan Zhang

Pachiappan Arjunan

Yang Li

Xu Hou

Anil Kumar

Lijin Dong

Affiliations

Soon will be listed here.

Abstract

Despite its early discovery and high sequence homology to the other VEGF family members, the biological function of VEGF-B remained debatable for a long time, and VEGF-B has received little attention from the field thus far. Recently, we and others have found that (1) VEGF-B is a potent survival factor for different types of cells by inhibiting apoptosis via suppressing the expression of BH3-only protein and other apoptotic/cell death-related genes. (2) VEGF-B has a negligible role in inducing blood vessel growth in most organs. Instead, it is critically required for blood vessel survival. VEGF-B targeting inhibited pathological angiogenesis by abolishing blood vessel survival in different animal models. (3) Using different types of neuro-injury and neurodegenerative disease models, VEGF-B treatment protected endangered neurons from apoptosis without inducing undesired blood vessel growth or permeability. Thus, VEGF-B is the first member of the VEGF family that has a potent survival/anti-apoptotic effect, while lacking a general angiogenic activity. Our work thus advocates that the major function of VEGF-B is to act as a "survival", rather than an "angiogenic" factor and implicates a therapeutic potential of VEGF-B in treating different types of vascular and neurodegenerative diseases.

Citing Articles

Beyond vessels: unraveling the impact of VEGFs on neuronal functions and structure.

Aksan B, Mauceri D J Biomed Sci. 2025; 32(1):33.

PMID: 40050849 PMC: 11884128. DOI: 10.1186/s12929-025-01128-8.

Possibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia.

Belenichev I, Popazova O, Yadlovskyi O, Bukhtiyarova N, Ryzhenko V, Pavlov S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861168 PMC: 11768627. DOI: 10.3390/ph18010106.

The Gene Variants and the Effectiveness of Platelet-Rich Plasma Treatment of Lateral Elbow Tendinopathy: A Prospective Cohort Study with a Two-Year Follow-Up.

Jarosz A, Nowak T, Szyluk K, Balcerzyk-Matic A, Iwanicki T, Iwanicka J Int J Mol Sci. 2024; 25(23).

PMID: 39684876 PMC: 11642232. DOI: 10.3390/ijms252313166.

Elevated hydrostatic pressure disturbs expression of growth factors in human renal epithelial cells.

Yan C, Xiao J, Peng Y, Li T PLoS One. 2024; 19(9):e0310001.

PMID: 39240898 PMC: 11379293. DOI: 10.1371/journal.pone.0310001.

Interleukin-6 as a Director of Immunological Events and Tissue Regenerative Capacity in Hemodialyzed Diabetes Patients.

Trandafir M, Savu O, Pasarica D, Bleotu C, Gheorghiu M Med Sci (Basel). 2024; 12(2).

PMID: 38921685 PMC: 11205729. DOI: 10.3390/medsci12020031.

References

Reichelt M, Shi S, Hayes M, Kay G, Batch J, Gole G . Vascular endothelial growth factor-B and retinal vascular development in the mouse. Clin Exp Ophthalmol. 2003; 31(1):61-5. DOI: 10.1046/j.1442-9071.2003.00602.x. View

Ferrara N, Chen H, Dowd M, Lu L, OShea K, Hillan K . Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996; 380(6573):439-42. DOI: 10.1038/380439a0. View

Wright C . Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model. Clin Exp Pharmacol Physiol. 2002; 29(11):1035-9. DOI: 10.1046/j.1440-1681.2002.03773.x. View

Wafai R, Tudor E, Angus J, Wright C . Vascular effects of FGF-2 and VEGF-B in rabbits with bilateral hind limb ischemia. J Vasc Res. 2008; 46(1):45-54. DOI: 10.1159/000139132. View

Lahteenvuo J, Lahteenvuo M, Kivela A, Rosenlew C, Falkevall A, Klar J . Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation. 2009; 119(6):845-56. DOI: 10.1161/CIRCULATIONAHA.108.816454. View

Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, de Mol M . Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001; 7(5):575-83. DOI: 10.1038/87904. View

Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K . Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol. 2008; 28(9):1614-20. PMC: 2753879. DOI: 10.1161/ATVBAHA.107.158725. View

Sun Y, Jin K, Childs J, Xie L, Mao X, Greenberg D . Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice. J Cereb Blood Flow Metab. 2004; 24(10):1146-52. DOI: 10.1097/01.WCB.0000134477.38980.38. View

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F . Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002; 8(8):831-40. DOI: 10.1038/nm731. View

10.

Mould A, Tonks I, Cahill M, Pettit A, Thomas R, Hayward N . Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. 2003; 48(9):2660-9. DOI: 10.1002/art.11232. View

11.

Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y . Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997; 16(13):3898-911. PMC: 1170014. DOI: 10.1093/emboj/16.13.3898. View

12.

Bellomo D, Headrick J, Silins G, Paterson C, Thomas P, Gartside M . Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res. 2000; 86(2):E29-35. DOI: 10.1161/01.res.86.2.e29. View

13.

Ogawa S, Oku A, Sawano A, Yamaguchi S, Yazaki Y, Shibuya M . A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem. 1998; 273(47):31273-82. DOI: 10.1074/jbc.273.47.31273. View

14.

Shih S, Ju M, Liu N, Mo J, Ney J, Smith L . Transforming growth factor beta1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc Natl Acad Sci U S A. 2003; 100(26):15859-64. PMC: 307658. DOI: 10.1073/pnas.2136855100. View

15.

Kawamura H, Li X, Goishi K, van Meeteren L, Jakobsson L, Cebe-Suarez S . Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood. 2008; 112(9):3638-49. PMC: 2572791. DOI: 10.1182/blood-2007-12-125856. View

16.

Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch A . VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A. 2009; 106(15):6152-7. PMC: 2669337. DOI: 10.1073/pnas.0813061106. View

17.

Liu W, Parikh A, Stoeltzing O, Fan F, McCarty M, Wey J . Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF. Cytokine. 2005; 32(5):206-12. DOI: 10.1016/j.cyto.2005.09.009. View

18.

Brkovic A, Sirois M . Vascular permeability induced by VEGF family members in vivo: role of endogenous PAF and NO synthesis. J Cell Biochem. 2006; 100(3):727-37. DOI: 10.1002/jcb.21124. View

19.

Aase K, von Euler G, Li X, Ponten A, Thoren P, Cao R . Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation. 2001; 104(3):358-64. DOI: 10.1161/01.cir.104.3.358. View

20.

Nash A, Baca M, Wright C, Scotney P . The biology of vascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther. 2005; 19(1):61-9. DOI: 10.1016/j.pupt.2005.02.007. View